Prevalence and cardiovascular disease risk differences for erectile dysfunction patients by three metabolic syndrome definitions

Abstract

There is growing evidence of a link between ED, metabolic syndrome (MS) and cardiovascular disease (CVD). The study was to explore the prevalence of MS using three different definitions (World Health Organization (WHO), International Diabetes Foundation (IDF) and Adult Treatment Panel III (ATP III)), and to compare the association of CVD in ED outpatients using these definitions. This study enrolled 254 participants with a mean age of 55.3±0.9 years (range, 21 to 81 years) with ED as diagnosed by International Index of Erectile Function score. All participants underwent MS evaluation based on the three criteria. Differences of MS prevalence, demographical characteristics, biochemical profiles, pro-inflammatory and inflammatory markers, echocardiographic characteristics and the association with Framingham cardiac risk score (FCRS) were compared. The presence of diabetes mellitus (DM) in the WHO group and high waist girth in the IDF group were significant because of the necessity of respective criteria. The MS prevalence in the WHO, IDF and ATP III groups was 30.7, 34.3 and 36.6%, respectively (P ¼ 0.367). The degrees of agreement among each definition were substantial to perfect. No significant findings in echocardiographic characteristics, biochemical, inflammatory and pro-inflammatory markers were noted. The FCRS showed borderline nonsignificant difference (17.9 ± 0.4, 16.8 ± 0.4 and 16.9 ± 0.4, P ¼ 0.079); however, the FCRS was more closely correlated with the WHO than with the IDF and ATP III (Spearman's correlation coefficients were 0.522, 0.531 and 0.462, respectively; P ¼ 0.021). In patients o 55 years of age and those who smoke, the Spearman's correlation in the WHO group was significantly higher than in the IDF and ATP III groups. The prevalence of the MS using different definitions in ED patients was not different. The WHO-defined MS was more closely associated with CVD.

Prevalence and Determinants of Metabolic Syndrome among Women in Chinese Rural Areas

“…Data from a Korean population showed the prevalence of MS for women was 26.6% according to the IDF and 31.9% according to the ATPIII-modified [24]. In a recent study in Taiwan, the prevalence of MS in the IDF and ATPIII-modified was 34.3% and 36.6% [7]. The prevalence of these two studies was higher than in our study.…”

“…Recent reports suggest that MS criteria are met by approximately 1 in 3 adults [7], [8]. MS not only increases cardiovascular morbidity and mortality but also increases the risk of developing diabetes because its components represent major risk factors for impaired glucose metabolism [9].…”

Magnitude, components and predictors of metabolic syndrome in Northern Ethiopia: Evidences from regional NCDs STEPS survey, 2016

“…Individuals with metabolic syndrome are five times more susceptible to chronic diseases [3][4][5][6] and becoming an important cause of morbidity and mortality in Africa. Pieces of evidences suggested that contributing factors were rapid demographic transition, changing behaviors, and lifestyles [2][3][4][5]. The high MetS prevalence was observed in Africa ranged from 17-25% [7].…”

“…However, in Sub-Saharan Africa (SSA) its prevalence will be 59% to 179% in 2030 [2][3][4][5]. Even though most of the studies on MetS were conducted in North America, Europe, and Asia [12][13][14], its impact was high in sub-Saharan African; like Kenya (25.6%), and Tanzania (38%) [15][16][17].…”

Papel do NLRP3 na disfunção erétil em modelo de hipertensão DOCA/sal e sua possível ativação por ET-1

“…Além disso, a hipertensão arterial está frequentemente associada a gênese ou progressão da DE (Muller e Mulhall, 2006;Shabsigh et al, 2008;Chang et al, 2011).…”